Stem Cell Research & Therapy,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Aug. 13, 2024
Hemorrhagic
stroke
is
a
devastating
cerebrovascular
event
with
high
rate
of
early
mortality
and
long-term
disability.
The
therapeutic
potential
mesenchymal
stem
cell-derived
extracellular
vesicles
(MSC-EVs)
for
neurological
conditions,
such
as
intracerebral
hemorrhage
(ICH),
has
garnered
considerable
interest,
though
their
mechanisms
action
remain
poorly
understood.
Fluids and Barriers of the CNS,
Journal Year:
2022,
Volume and Issue:
19(1)
Published: July 25, 2022
Abstract
Extracellular
vesicles
(EVs)
are
particles
naturally
released
from
cells
that
delimited
by
a
lipid
bilayer
and
unable
to
replicate.
How
the
EVs
cross
Blood–Brain
barrier
(BBB)
in
bidirectional
manner
between
bloodstream
brain
parenchyma
remains
poorly
understood.
Most
vitro
models
have
evaluated
this
event
relied
on
monolayer
transwell
or
microfluidic
organ-on-a-chip
techniques
do
not
account
for
combined
effect
of
all
cellular
layers
constitute
BBB
at
different
sites
Central
Nervous
System.
There
has
been
direct
transcytosis
visualization
through
mammals
vivo,
evidence
comes
vivo
experiments
zebrafish.
Literature
is
scarce
topic,
describing
mechanisms
motion
inconsistent.
This
review
will
focus
methodologies
used
evaluate
transcytosis,
how
overcome
fundamental
structure,
discuss
potential
methodological
approaches
future
analyses
clarify
these
issues.
Understanding
be
essential
their
use
as
vehicles
pharmacology
therapeutics.
Theranostics,
Journal Year:
2022,
Volume and Issue:
12(11), P. 4879 - 4903
Published: Jan. 1, 2022
In
recent
decades,
extracellular
vesicles
(EVs),
as
bioactive
cell-secreted
nanoparticles
which
are
involved
in
various
physiological
and
pathological
processes
including
cell
proliferation,
immune
regulation,
angiogenesis
tissue
repair,
have
emerged
one
of
the
most
attractive
nanotherapeutics
for
regenerative
medicine.
Herein
we
provide
a
systematic
review
latest
progress
EVs
applications.
Firstly,
will
briefly
introduce
biogenesis,
function
isolation
technology
EVs.
Then,
underlying
therapeutic
mechanisms
native
unmodified
engineering
strategies
modified
entities
be
discussed.
Subsequently,
main
focus
placed
on
repair
regeneration
applications
organs
brain,
heart,
bone
cartilage,
liver
kidney,
well
skin.
More
importantly,
current
clinical
trials
medicine
also
highlighted.
Finally,
future
challenges
insightful
perspectives
currently
developed
EV-based
biomedicine
short,
opened
new
horizons
biologists,
chemists,
nanoscientists,
pharmacists,
clinicians,
making
possible
powerful
tools
therapies
Theranostics,
Journal Year:
2023,
Volume and Issue:
13(12), P. 4138 - 4165
Published: Jan. 1, 2023
Neurodegenerative
diseases
are
characterized
by
the
progressive
loss
of
neurons
and
intricate
interactions
between
different
cell
types
within
affected
regions.Reliable
biomarkers
that
can
accurately
reflect
disease
activity,
diagnose,
monitor
progression
neurodegenerative
crucial
for
development
effective
therapies.However,
identifying
suitable
has
been
challenging
due
to
heterogeneous
nature
these
diseases,
affecting
specific
subsets
in
brain
regions.One
promising
approach
promoting
regeneration
recovery
involves
transplantation
mesenchymal
stem
cells
(MSCs).MSCs
have
demonstrated
ability
modulate
immune
system,
promote
neurite
outgrowth,
stimulate
angiogenesis,
repair
damaged
tissues,
partially
through
release
their
extracellular
vesicles
(EVs).MSC-derived
EVs
retain
some
therapeutic
characteristics
parent
MSCs,
including
regulate
facilitate
tissue
repair.This
review
aims
explore
potential
MSC-derived
as
an
emerging
strategy
highlighting
role
modulating
neuronal
recovery.By
elucidating
mechanisms
which
exert
effects,
we
advance
our
understanding
leverage
novel
treatment
approaches
field
diseases.
Journal of Controlled Release,
Journal Year:
2023,
Volume and Issue:
356, P. 493 - 506
Published: March 15, 2023
Diseases
of
the
central
nervous
system
(CNS)
are
challenging
to
treat,
mainly
due
blood-brain
barrier
(BBB),
which
restricts
drugs
in
circulation
from
entering
target
regions
brain.
To
address
this
issue
extracellular
vesicles
(EVs)
have
gained
increasing
scientific
interest
as
carriers
able
cross
BBB
with
multiplex
cargos.
EVs
secreted
by
virtually
every
cell,
and
their
escorted
biomolecules
part
an
intercellular
information
gateway
between
cells
within
brain
other
organs.
Scientists
undertaken
efforts
safeguard
inherent
features
therapeutic
delivery
vehicles,
such
protecting
transferring
functional
cargo,
well
loading
them
small
molecules,
proteins,
oligonucleotides
targeting
specific
cell
types
for
treatment
CNS
diseases.
Here,
we
review
current
emerging
approaches
that
engineer
EV
surface
cargo
improve
responses
We
summarize
existing
applications
engineered
a
platform
diseases,
some
been
evaluated
clinically.
Advanced Healthcare Materials,
Journal Year:
2022,
Volume and Issue:
11(21)
Published: Sept. 2, 2022
Extracellular
vesicles
(EVs),
acting
as
an
important
ingredient
of
intercellular
communication
through
paracrine
actions,
have
gained
tremendous
attention
in
the
field
tissue
engineering
(TE).
Moreover,
these
nanosized
extracellular
particles
(30-140
nm)
can
be
incorporated
into
biomaterials
according
to
different
principles
facilitate
signal
delivery
various
regenerative
processes
directly
or
indirectly.
Bioactive
carrier
will
extend
retention
time
and
realize
controlled
release
EVs,
which
further
enhance
their
therapeutic
efficiency
regeneration.
Herein,
basic
biological
characteristics
EVs
are
first
introduced,
then
outstanding
performance
exerting
direct
impacts
on
target
cells
regeneration
well
indirect
effects
promoting
angiogenesis
regulating
immune
environment,
due
specific
functional
components
(nucleic
acid,
protein,
lipid,
etc.),
is
emphasized.
Furthermore,
design
ideas
for
suitable
EV-loaded
also
demonstrated.
In
end,
this
review
highlights
engineered
strategies,
aim
at
solving
problems
related
natural
such
highly
heterogeneous
functions,
inadequate
targeting
capabilities,
insufficient
yield
scalability,
etc.,
thus
pertinence
clinical
potential
EV-based
approaches
TE.
Molecular Therapy,
Journal Year:
2023,
Volume and Issue:
31(5), P. 1275 - 1292
Published: April 6, 2023
Machado-Joseph
disease
(MJD)/spinocerebellar
ataxia
type
3
(SCA3)
is
the
most
common
autosomal
dominantly
inherited
worldwide.
It
caused
by
an
over-repetition
of
trinucleotide
CAG
within
ATXN3
gene,
which
confers
toxic
properties
to
ataxin-3
(ATXN3)
species.
RNA
interference
technology
has
shown
promising
therapeutic
outcomes
but
still
lacks
a
non-invasive
delivery
method
brain.
Extracellular
vesicles
(EVs)
emerged
as
vehicles
due
their
capacity
deliver
small
nucleic
acids,
such
microRNAs
(miRNAs).
miRNAs
were
found
be
enriched
into
EVs
specific
signal
motifs
designated
ExoMotifs.
In
this
study,
we
aimed
at
investigating
whether
ExoMotifs
would
promote
packaging
artificial
used
treat
MJD/SCA3.
We
that
miRNA-based
silencing
sequences,
associated
with
ExoMotif
GGAG
and
ribonucleoprotein
A2B1
(hnRNPA2B1),
retained
silence
mutant
(mutATXN3)
3-fold
EVs.
Bioengineered
containing
neuronal
targeting
peptide
RVG
on
surface
significantly
decreased
mutATXN3
mRNA
in
primary
cerebellar
neurons
from
MJD
YAC
84.2
novel
dual-luciferase
mouse
model
upon
daily
intranasal
administration.
Altogether,
these
findings
indicate
bioengineered
carrying
sequences
are
vehicle
for
brain
therapy.
Nanoscale,
Journal Year:
2023,
Volume and Issue:
15(26), P. 10904 - 10938
Published: Jan. 1, 2023
This
review
summarizes
recent
advances
in
extracellular
vesicle-based
carriers
for
glioblastoma
diagnosis
and
therapy,
points
out
the
current
challenges
perspectives.
CNS & Neurological Disorders - Drug Targets,
Journal Year:
2024,
Volume and Issue:
23(11), P. 1357 - 1370
Published: Feb. 14, 2024
Extracellular
vesicles
or
exosomes,
often
known
as
EVs,
have
acquired
significant
attention
in
the
investigations
of
traumatic
brain
injury
(TBI)
and
a
distinct
advantage
actively
researching
fundamental
mechanisms
underlying
various
clinical
symptoms
diagnosing
wide
range
cases.
The
mesenchymal
stem
cells
(MSCs)
can
produce
release
which
offer
therapeutic
benefits.
Exosomes
are
tiny
membranous
produced
by
cellular
entities
originating
from
endosomes.
Several
studies
reported
that
administering
MSC-derived
exosomes
through
intravenous
infusions
improves
neurological
recovery
promotes
neuroplasticity
rats
with
damage.
advantages
be
attributed
to
microRNAs
(miRNAs),
small
non-coding
regulatory
RNAs
significantly
impact
regulation
posttranscriptional
genes.
Exosome-based
therapies,
do
not
involve
cells,
lately
gained
interest
potential
breakthrough
enhancing
accelerating
for
injuries
neurodegenerative
diseases.
This
article
explores
benefits
drawbacks
exosome
treatment
while
emphasizing
latest
advancements
this
field
significance.